Alto Neuroscience Execs Sued Over Rosy Drug Claims
By Lauren Berg · October 7, 2025, 10:53 PM EDT
An Alto Neuroscience investor claims CEO Amit Etkin and other directors overstated the efficacy of the psychiatric biotech company's lead drug candidate for treating major depressive disorder, according to a lawsuit...
To view the full article, register now.